Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(50.0%)
Phase 1
4(50.0%)
8Total
Phase 2(4)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03401788Phase 2Active Not Recruiting

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Role: lead

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Role: lead

NCT03634540Phase 2Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Role: lead

NCT03108066Phase 2Completed

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

Role: lead

NCT02293980Phase 1Active Not Recruiting

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Role: lead

NCT03216499Phase 2Completed

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

Role: collaborator

NCT03445169Phase 1Completed

A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets

Role: lead

NCT02553356Phase 1Completed

PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers

Role: lead

All 8 trials loaded